Halozyme Therapeutics Inc. (HALO) Stock Price Down 3.2%
Shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) were down 3.2% during mid-day trading on Wednesday . The stock traded as low as $11.90 and last traded at $12.10, with a volume of 644,154 shares traded. The stock had previously closed at $12.50.
Several equities analysts have commented on HALO shares. Canaccord Genuity reiterated a “buy” rating and issued a $11.00 price objective on shares of Halozyme Therapeutics in a report on Monday, June 6th. Wells Fargo & Co. reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 8th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $15.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, June 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. Halozyme Therapeutics has a consensus rating of “Buy” and an average price target of $16.11.
The firm’s market cap is $1.59 billion. The company’s 50-day moving average is $10.37 and its 200-day moving average is $9.76.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/halozyme-therapeutics-inc-halo-stock-price-down-3-2.html
Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.06. Halozyme Therapeutics had a negative return on equity of 234.15% and a negative net margin of 44.90%. The business had revenue of $33.30 million for the quarter, compared to analysts’ expectations of $29.94 million. During the same period last year, the business earned $0.02 EPS. The business’s revenue was down 23.3% on a year-over-year basis. Analysts anticipate that Halozyme Therapeutics Inc. will post ($0.91) EPS for the current fiscal year.
A number of institutional investors have recently modified their holdings of HALO. Vanguard Group Inc. boosted its position in shares of Halozyme Therapeutics by 0.9% in the second quarter. Vanguard Group Inc. now owns 7,608,228 shares of the biopharmaceutical company’s stock valued at $65,658,000 after buying an additional 71,340 shares during the period. First Eagle Investment Management LLC boosted its position in shares of Halozyme Therapeutics by 6.6% in the second quarter. First Eagle Investment Management LLC now owns 7,101,000 shares of the biopharmaceutical company’s stock valued at $61,282,000 after buying an additional 437,300 shares during the period. FMR LLC boosted its position in shares of Halozyme Therapeutics by 12.5% in the second quarter. FMR LLC now owns 6,691,247 shares of the biopharmaceutical company’s stock valued at $57,745,000 after buying an additional 745,567 shares during the period. BlackRock Fund Advisors boosted its position in shares of Halozyme Therapeutics by 1.2% in the second quarter. BlackRock Fund Advisors now owns 4,352,218 shares of the biopharmaceutical company’s stock valued at $37,560,000 after buying an additional 49,489 shares during the period. Finally, State Street Corp boosted its position in shares of Halozyme Therapeutics by 3.1% in the second quarter. State Street Corp now owns 3,578,450 shares of the biopharmaceutical company’s stock valued at $30,880,000 after buying an additional 105,978 shares during the period. Institutional investors and hedge funds own 80.41% of the company’s stock.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.